Relmada Therapeutics RLMD
NASDAQ RLMD
$3.26 +0.05 (+1.56%)
As of: Oct 22, 2026 · 10:59 AM EDT

Relmada Therapeutics (RLMD) Net Margin (2012 - 2023)

Updated

Relmada Therapeutics' Net Margin was -877.66% in FY2013, down 725.89 percentage points from -151.77% in FY2012.

Analysis

Relmada Therapeutics (RLMD) Net Margin (2012 - 2023) Analysis & Trends

  • Per Business Quant data, Net Margin in earlier years was -151.77% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,167.56 Bn 1,136.14 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 635.76 Bn 554.29 Bn 17.26 Bn 21.86%
3 AbbVie 503.27 Bn 476.38 Bn 12.70 Bn 21.27%
4 Merck 377.51 Bn 331.89 Bn 12.21 Bn -8.04%
5 Novartis Ag 304.07 Bn 268.06 Bn 11.24 Bn 22.65%
6 Astrazeneca 267.53 Bn 241.22 Bn 12.86 Bn 16.30%
7 Amgen 242.06 Bn 197.46 Bn 7.24 Bn 23.62%
8 Gilead Sciences 194.26 Bn 168.46 Bn 6.22 Bn -134.51%
9 Pfizer 172.62 Bn 119.27 Bn 10.94 Bn -1.65%
10 Relmada Therapeutics 368.03 Mn -190.56 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -1,998.46%
Sep 30, 2023 -1,665.00%
Jun 30, 2023 -1,855.86%
Mar 31, 2023 -4,866.05%
Dec 31, 2022 -3,509.55%
Sep 30, 2022 -14,821.12%
Jun 30, 2022 -9,696.84%
Mar 31, 2022 -12,620.63%
Dec 31, 2021 -95,591.41%
Dec 31, 2020 -9,257.73%
Sep 30, 2020 -4,652.49%
Sep 30, 2019 -9,677.96%
Mar 31, 2019 -16,852.16%
Sep 30, 2017 -177.67%
Jun 30, 2017 -793,017.96%
Mar 31, 2017 -418,920.51%
Jun 30, 2016 -174,967.88%
Mar 31, 2016 -239,046.27%
Jun 30, 2015 -3,776,788.28%
Mar 31, 2015 -106,945.77%
API Access

Relmada Therapeutics Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY